Novartis Gene Therapy Zolgensma Will Be Approved.
The FDA Approves a Merck Combination for First-Line Renal Cell Carcinoma.
RegenxBio and Exelixis Are in Great Shape.
Novartis' Gene Therpay Product Zolgensma
The FDA submission of the gene therapy product Zolgensma was based on positive findings from a trial of 15 babies treated with it. Recently; however, at the Orlando meeting of the Muscular Dystrophy Association Novartis (NVS) presented interim results for 22 babies with Type 1 . . .